治疗方式对与人乳头状瘤病毒相关的口咽癌患者报告生活质量的影响
前瞻性队列研究纳入101例AJCC第8版T1-3 N0-2 HPV+口咽鳞癌患者,比较手术、术后放疗、术后放化疗、根治性放疗或根治性放化疗对患者报告生活质量的影响。结果显示单纯手术组治疗后生活质量影响最小,手术加放化疗组症状负担最高,所有治疗方式患者在1年时均持续存在味觉/嗅觉困难。
要点
- 单纯手术组报告的治疗后生活质量影响最低,手术加放化疗组症状负担最高。
- 手术加放化疗组和根治性放化疗组在1年时唾液腺功能障碍和社会进食问题显著差于单纯手术组。
- 所有治疗方式患者在1年时均持续存在有临床意义的味觉/嗅觉困难。
核心结论
- HPV+口咽鳞癌患者单纯手术后报告的治疗后生活质量影响最低,而手术加放化疗后报告的症状负担最高。
- 鉴于可能需辅助放化疗,仔细选择根治性手术患者很重要。
- 所有治疗方式患者在1年时均可能经历持续的味觉和嗅觉困难。
研究设计与样本
- 前瞻性队列研究,纳入101例美国癌症联合委员会(AJCC)第8版T1-3 N0-2 HPV+口咽鳞癌患者,在学术医疗中心完成欧洲癌症研究与治疗组织生活质量核心问卷及头颈模块,于治疗前、治疗后3个月和1年评估。
- 将平均评分变化与已发表的最小临床重要差异进行比较。
主要发现
- 患者接受单纯手术(SA:N=42,42%)、手术加辅助放疗(S-RT:N=10,10%)、手术加辅助放化疗(S-CRT:N=8,8%)、根治性放疗(RT:N=11,11%)或根治性放化疗(CRT:N=30,30%)。
- SA、S-[C]RT和[C]RT患者在1年时均报告有临床意义的味觉/嗅觉困难。
- S-[C]RT和[C]RT患者在1年时报告的唾液腺功能障碍和社会进食问题在统计学和临床上均显著差于SA。
- S-[C]RT患者在3个月时报告的疲劳和头颈疼痛在统计学和临床上均显著差于[C]RT和SA患者,但1年时恢复正常。
- S-CRT与S-RT相比,在3个月时躯体功能、角色功能和吞咽困难在统计学和临床上均更差,但治疗后1年时差异已消失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prospectively compare the impact of treatment modality on patient-reported quality of life (QOL) in human papillomavirus-associated oropharynx squamous cell carcinoma (HPV + OPSCC). STUDY DESIGN: Prospective cohort study. SETTING: Academic medical center. METHODS: One hundred one patients with American Joint Committee on Cancer (AJCC) 8th edition T1-3 N0-2 HPV + OPSCC completed the European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire and Head and Neck Module pretreatment and 3-month and 1-year posttreatment. Mean score changes were compared to published minimal clinically important differences. RESULTS: Patients underwent surgery alone (SA: N = 42, 42%), surgery with adjuvant radiation (S-RT: N = 10, 10%), surgery with adjuvant chemoradiation (S-CRT: N = 8, 8%), definitive radiation (RT: N = 11, 11%), or definitive chemoradiation (CRT: N = 30, 30%). SA, S-[C]RT, and [C]RT patients all reported clinically significant difficulty with sense of taste/smell persisting at 1 year. S-[C]RT and [C]RT patients reported statistically and clinically significant worse salivary dysfunction and problems with social eating at 1 year than SA. S-[C]RT patients reported statistically and clinically significant worse fatigue and head and neck pain compared to [C]RT and SA patients at 3 months, but normalized at 1 year. S-CRT compared to S-RT had statistically and clinically worse physical and role functioning and swallowing difficulties at 3 months but this difference was resolved by 1-year posttreatment. CONCLUSION: HPV + OPSCC patients after SA report the lowest posttreatment QOL impact, whereas after S-CRT report the highest symptom burden. Careful selection for definitive surgery is important given the possibility of adjuvant CRT. Patients can experience persistent sense taste and smell difficulties at 1 year with all treatment modalities. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:1687-1695, 2024.
引用
- Plonowska-Hirschfeld KA, Gulati A, Stephens EM, et al. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma. Laryngoscope. 2023. PMID: 37767815. doi:10.1002/lary.31065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。